- Home
- TRIP vs CGON Comparison
TRIP vs CGON Comparison
Compare TRIP & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRIP
- CGON
- Stock Information
- Founded
- TRIP 2000
- CGON 2010
- Country
- TRIP United States
- CGON United States
- Employees
- TRIP N/A
- CGON N/A
- Industry
- TRIP Computer Software: Programming Data Processing
- CGON
- Sector
- TRIP Technology
- CGON
- Exchange
- TRIP Nasdaq
- CGON NYSE
- Market Cap
- TRIP 1.6B
- CGON 1.3B
- IPO Year
- TRIP 2011
- CGON 2024
- Fundamental
- Price
- TRIP $14.94
- CGON $24.13
- Analyst Decision
- TRIP Hold
- CGON Strong Buy
- Analyst Count
- TRIP 14
- CGON 11
- Target Price
- TRIP $17.50
- CGON $62.90
- AVG Volume (30 Days)
- TRIP 2.5M
- CGON 2.0M
- Earning Date
- TRIP 05-07-2025
- CGON 05-16-2025
- Dividend Yield
- TRIP N/A
- CGON N/A
- EPS Growth
- TRIP 114.07
- CGON N/A
- EPS
- TRIP 0.37
- CGON N/A
- Revenue
- TRIP $1,838,000,000.00
- CGON $1,139,000.00
- Revenue This Year
- TRIP $6.27
- CGON N/A
- Revenue Next Year
- TRIP $7.64
- CGON $16,237.24
- P/E Ratio
- TRIP $38.73
- CGON N/A
- Revenue Growth
- TRIP 1.44
- CGON 461.08
- 52 Week Low
- TRIP $10.43
- CGON $14.80
- 52 Week High
- TRIP $27.63
- CGON $40.47
- Technical
- Relative Strength Index (RSI)
- TRIP 68.08
- CGON 51.00
- Support Level
- TRIP $12.46
- CGON $21.00
- Resistance Level
- TRIP $13.06
- CGON $30.23
- Average True Range (ATR)
- TRIP 0.52
- CGON 2.31
- MACD
- TRIP 0.35
- CGON 0.16
- Stochastic Oscillator
- TRIP 94.64
- CGON 34.09
About TRIP TripAdvisor Inc.
Tripadvisor is the world's leading travel metasearch company. Its platform offers 1 billion reviews and information on several million accommodations, restaurants, experiences, airlines, and cruises. In 2024, 52% of revenue came from the company's core Brand Tripadvisor segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 46% of sales in 2024, and TheFork, its dining brand, represented 10% of revenue (about 8% of sales were intersegment, which are eliminated from consolidated revenue).
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.